Stock Events

Stock Events

Absci 

$2.99
156
-$0.05-1.64% Today

Statistics

Day High
3.02
Day Low
2.95
52W High
-
52W Low
-
Volume
40,407
Avg. Volume
-
Mkt Cap
449.61M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2025
Q4 2025
Next
-0.21
-0.2
-0.19
-0.18
Expected EPS
-0.194286
Actual EPS
N/A

Financials

-2,274.06%Profit Margin
Unprofitable
2021
2022
2023
2024
9.07MRevenue
-206.21MNet Income

Analyst Ratings

$7.50Average Price Target
The highest estimate is 8.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABSI.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Twist Bioscience
TWST
Mkt Cap3.08B
Twist Bioscience operates in the synthetic biology space, offering products that compete directly with Absci's protein production and drug discovery platforms.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing, a technology that can be seen as complementary but also competitive to Absci's AI-driven drug discovery and development.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine focuses on gene editing, directly competing with Absci in the development of novel therapeutics through advanced biotechnologies.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is another key player in the gene editing field, competing with Absci in the race to develop new genetic medicines.
Beam Therapeutics
BEAM
Mkt Cap2.51B
Beam Therapeutics specializes in base editing, a form of gene editing, positioning it as a competitor in the innovative therapeutic development space alongside Absci.
Adaptive Biotechnologies
ADPT
Mkt Cap2.28B
Adaptive Biotechnologies offers immune-driven medicine solutions, competing with Absci in the broader biotech space focused on leveraging biological systems for drug discovery.
Pacific Biosciences of California
PACB
Mkt Cap404.68M
Pacific Biosciences provides sequencing solutions that can be used in drug discovery and development, competing with Absci's technology platform.
Illumina
ILMN
Mkt Cap19.48B
Illumina offers genomic sequencing technologies, which are essential for modern drug discovery and development, thus competing with Absci's integrated drug and protein production platforms.
Syros Pharmaceuticals
SYRS
Mkt Cap5,366
Syros Pharmaceuticals is engaged in drug discovery and development using gene control as a mechanism, which places it in competition with Absci's approach to creating and optimizing protein-based therapeutics.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics focuses on genomic medicine, including gene therapy and gene editing, competing with Absci in the development of novel genomic-based therapies.

About

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Show more...
CEO
ISIN
US00091E1091

Listings

XNAS
US
ABSI
BOATS
BOATS
ABSI.BOATS

0 Comments

Share your thoughts

FAQ

What is Absci stock price today?▼
The current price of ABSI.BOATS is $2.99 USD — it has decreased by -1.64% in the past 24 hours. Watch Absci stock price performance more closely on the chart.
What is Absci stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Absci stocks are traded under the ticker ABSI.BOATS.
What is Absci market cap?▼
Today Absci has the market capitalization of 449.61M
When is the next Absci earnings date?▼
Absci is going to release the next earnings report on May 19, 2026.
What were Absci earnings last quarter?▼
ABSI.BOATS earnings for the last quarter are -0.2 USD per share, whereas the estimation was -0.18 USD resulting in a -12.5% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Absci revenue for the last year?▼
Absci revenue for the last year amounts to 9.07M USD.
What is Absci net income for the last year?▼
ABSI.BOATS net income for the last year is -206.21M USD.
When did Absci complete a stock split?▼
Absci has not had any recent stock splits.